

10/560230

IAP13 RECEIVED PTO 12 DEC 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NO. 40072-0026US

In re patent application of:
Takeshi TABIRA et al.

Applic. No.: Unassigned

Art Unit: Unassigned

Filed: December 12, 2005

Examiner: Unassigned

For: RECOMBINANT ADENO-ASSOCIATED VIRUS VECTOR FOR TREATMENT OF
ALZHEIMER DISEASE

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56 and 37 CFR §1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97. A copy of each of the listed documents are being submitted to comply with the provisions of 37 C.F.R. §1.97-1.99.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.

IAP13 Rec'd PCT/PTO 12 DEC 2005
RELEVANCE

These documents came to the Applicants' attention during a search of the corresponding international application. A copy of the International Search Report setting forth the portion of each reference considered relevant by the examiner is attached.

TIMING/FEE

The instant Information Disclosure Statement is being filed in compliance with 37 CFR §1.97(b) within three months from the filing date of the above-identified application, therefore, no fee is required in connection with its filing.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.


Date:

12/12/05

HELLER EHRMAN LLP
1717 Rhode Island Avenue, N.W.
Washington, D.C. 20036
Telephone: (202) 912-2000
Facsimile: (202) 912-2020

Respectfully submitted,

By



John P. Isacson
Attorney for Applicant
Reg. No.: 33,715

Customer No. 26633

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	Unassigned // 20
--------------------	------------------

Filing Date	December 12, 2005
-------------	-------------------

First Named Inventor	Takeshi TABIRA et al.
----------------------	-----------------------

Group Art Unit	Unassigned
----------------	------------

Examiner Name	Unassigned
---------------	------------

Attorney Docket Number	40072-0026US
------------------------	--------------

[illegible][illegible]

**Examiner
Signature**

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box ☒ PTO/SB/08A (08-00)

AP13 RECEIVED DEC 2005

+

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Unassigned 40072/560280
		Filing Date	December 12, 2005
		First Named Inventor	Takeshi TABIRA et al.
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	40072-0026US
Sheet	2	of	2

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A04	R.J. BLAND et al., "Generation of Rat Alzheimers Disease Models Utilizing Adeno-Associated Virus to Target Transgenes to the Hippocampus", Socety for Neuroscience Abstract Viewer and Itinerary Planner, 2002, Vol. 2002, pp. Abstract, No. 295.12	
	A05	MARTIN CITRON et al., "Mutation of the B-amyloid precursor protein in familial Alzheimer's disease increases B-protein production", Nature, December 17, 1992, pp. 672-674, Vol. 360	
	A06	JIE KANG et al., "The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor", Nature, February 19, 1987, pp. 733-736, Vol. 325	
	A07	P.A. LEWIS et al., "Expression of BRI-amyloid B peptide fusion proteins: a novel method for specific high-level expression of amyloid B peptides", Biochimica et Biophysica Acta, 2001, pp 58-62, Vol. 1537	
	A08	SHANG ZHEN ZHOU et al., "Adeno-associated Virus 2-mediated High Efficiency Gene Transfer into Immature and Mature Subsets of Hematopoietic Progenitor Cells in Human Umbilical Cord Blood", J. Exp. Med., 1994, pp. 1867-1875, Vol. 179	
	A09	E.M. JOHNSTONE et al., "Nuclear and Cytoplasmic Localization of the B-Amyloid Peptide (1-43) in Transfected 293 Cells", Biochemical and Biophysical Research Communications, 1996, pp. 710-718, Vol. 220, Article. No. 0469	
	A10	MATTHEW J. DURING et al., "An Oral Vaccine Against NMDAR1 with Efficacy in Experimental Stroke and Epilepsy", Science, February 25, 2000, pp. 1453-1460, Vol. 287	
	A11	ELISABETH TARKOWSKI et al., "Increased intrathecal levels of the angiogenic factors VEGF and TGF-B in Alzheimer's disease and vascular dementia", Neurobiology of Aging, 2002, pp. 237-243, Vol. 23	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.